Proposed Agenda & Faculty, 15-16 September 2023
08:00am
Registration and faculty breakfast
08:45am
Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education
Session I: Mutations and Classification of MPN and MDS
09:00am
CHIP and MPN,
Steffen Koschmieder, RWTH Aachen University, Germany
09:20am
CHIP and MDS,
Liran Shlush, Weizmann Institute of Science, Israel
09:40am
ICC vs WHO for MPN,
Alessandro M. Vannucchi, University of Florence, Italy
10:00am
ICC vs WHO for MDS,
Maria Teresa Voso, UOSD Diagnostica Avanzata Oncoematologica del Policlinico di Tor Vergata (PTV), Italy
10:20am
Panel Discussion
10:40am
Coffee Break
Session II: Polycythemia vera (PV)
11:00am
Debate I: Standard of care for low-risk PV: Phlebotomy,
Mary Frances McMullin, Queen’s University Belfast, Ireland
11:15am
Standard of care for low-risk PV: Interferon,
Tiziano Barbui, University of Bergamo, Italy
11:30am
Panel Discussion
11:40am
Debate II: Standard of care for high-risk PV: Interferon,
Heinz Gisslinger, Medical University of Vienna, Austria
11:55am
Standard of care for high-risk PV: Hydroxyurea/ruxolitinib,
Rajko Kušec, University hospital Dubrava Zagreb, Croatia
12:10pm
Panel Discussion
12:20pm
Lunch break
13:10pm
Independent Medical Education Symposium supported by GSK
14:00pm
Room refresh & Exhibition viewing
Session III: Essential Thrombocytopenia (ET) and special situations
14:30pm
What is “high-risk” ET? Current and future therapies,
Paola Guglielmelli, University of Florence, Italy
14:50pm
Pregnancy in MPN: State of the art management,
Martin Griesshammer, Ruhr-Universität Bochum, Germany
15:10pm
MPN and SVT: Diagnosis and management,
Jean-Jacques Kiladjian, Université Paris Cité, France
15:30pm
Panel Discussion
15:50pm
Coffee break
Session IV: Myelofibrosis (MF)
16:10pm
Management of early/prefibrotic MF: Does early intervention matter?,
Lucia Masarova , MD Anderson Cancer Center, USA
16:30pm
Cytopenic MF: emerging area for novel approaches,
Paola Guglielmelli, Univerisity of Florence, Italy
16:50pm
First line therapy for Int2/High risk MF: where is the field going?,
Alessandro Vannucchi, University of Florence, Italy
17:10pm
Panel Discussion
17:30pm
Wrap up for Day 1
Session V: Other MPNs and Overlap Syndromes
08:30am
Aggressive systemic mastocytosis: emerging therapeutic options,
Deepti Radia, Guy’s and St. Thomas’ NHS Foundation Trust, UK
08:50am
Eosinophilic neoplasms: emerging therapeutic options,
Andreas Reiter, University Medical Centre Mannheim, Germany
09:10am
Myeloproliferative Neoplasm-Unclassifiable (MPN-U),
Donal P McLornan, University College London Hospitals NHS Trust, UK
09:30am
CML the paradigm for MPN,
Elias Jabbour, MD Anderson Cancer Center, USA
09:50am
Panel Discussion
10:10am
Coffee Break
Session VI: Other MPNs and Overlap Syndromes (cont.)
10:30am
Clinical trials in MDS/MPN: How Can we stand alone,
Michael Savona, Vanderbilt University, Nashville, USA
10:50am
Diagnosis and management of MDS/MPN-U,
Andrew Kuykendall, Moffitt Cancer Center, Florida, USA
11:10am
An update on CMML,
Eric Solary, Université Paris-Saclay, France
11:30am
Panel Discussion
11:50pm
Lunch Break
Session VII: Hematopoietic stem cell transplantation (HSCT)
12:50pm
Debate: HSCT for MF: Earlier?,
Ruben Mesa, Wake Forest University in Winston-Salem, USA
13:10pm
Debate: HSCT for MF: Later?,
Ibrahim Yakoub-Agha, Lille University Hospital, Lille, France
13:20pm
Panel discussion
13:40pm
Debate: HSCT for MDS: Earlier?,
Matteo Della Porta, Humanitas University, Italy
14:00pm
Debate: HSCT for MDS: Later?,
Valeria Santini, University of Florence, Italy
14:20pm
Management of iron overload in MDS: who, when?,
Marlijn Hoeks, Radboud University Medical Centre (Radboudumc), Netherlands
14:40pm
Panel discussion
15:00pm
Coffee Break
Session VIII: Myelodysplastic Syndromes (MDS)
15:20pm
Standard and new drugs in higher risk MDS,
Thomas Clazeua, Centre Hospitalier Universitaire de Nice, France
15:40pm
Anemia in MDS and SF3B1 mutated MDS,
Luca Malcovati, IRCCS S. Matteo Hospital Foundation & University of Pavia, Italy
16:00pm
Standard and New drugs in low-risk MDS,
Rami Komrokji, MD Anderson Cancer Center, USA
16:20pm
The resistance to treatment especially hypomethylating agents,
Lucia Messingerova, Slovak Academy of Sciences, Slovakia
16:40pm
Managing secondary AML: from MDS and MPN,
Naval Daver, MD Anderson Cancer Center, USA
17:00pm
Panel discussion
17:20pm
Summary and Wrap up
08:00am
Registration and faculty breakfast
08:45am
Opening Introduction to the meeting - Ryan Fitzpatrick, CEO, MD Education
Session I: Mutations and Classification of MPN and MDS
09:00am
CHIP and MPN,
Steffen Koschmieder, RWTH Aachen University, Germany
09:20am
CHIP and MDS,
Liran Shlush, Weizmann Institute of Science, Israel
09:40am
ICC vs WHO for MPN,
Alessandro M. Vannucchi, University of Florence, Italy
10:00am
ICC vs WHO for MDS,
Maria Teresa Voso, UOSD Diagnostica Avanzata Oncoematologica del Policlinico di Tor Vergata (PTV), Italy
10:20am
Panel Discussion
10:40am
Coffee Break
Session II: Polycythemia vera (PV)
11:00am
Debate I: Standard of care for low-risk PV: Phlebotomy,
Mary Frances McMullin, Queen’s University Belfast, Ireland
11:15am
Standard of care for low-risk PV: Interferon,
Tiziano Barbui, University of Bergamo, Italy
11:30am
Panel Discussion
11:40am
Debate II: Standard of care for high-risk PV: Interferon,
Heinz Gisslinger, Medical University of Vienna, Austria
11:55am
Standard of care for high-risk PV: Hydroxyurea/ruxolitinib,
Rajko Kušec, University hospital Dubrava Zagreb, Croatia
12:10pm
Panel Discussion
12:20pm
Lunch break
13:10pm
Independent Medical Education Symposium supported by GSK
14:00pm
Room refresh & Exhibition viewing
Session III: Essential Thrombocytopenia (ET) and special situations
14:30pm
What is “high-risk” ET? Current and future therapies,
Paola Guglielmelli, University of Florence, Italy
14:50pm
Pregnancy in MPN: State of the art management,
Martin Griesshammer, Ruhr-Universität Bochum, Germany
15:10pm
MPN and SVT: Diagnosis and management,
Jean-Jacques Kiladjian, Université Paris Cité, France
15:30pm
Panel Discussion
15:50pm
Coffee break
Session IV: Myelofibrosis (MF)
16:10pm
Management of early/prefibrotic MF: Does early intervention matter?,
Lucia Masarova , MD Anderson Cancer Center, USA
16:30pm
Cytopenic MF: emerging area for novel approaches,
Paola Guglielmelli, Univerisity of Florence, Italy
16:50pm
First line therapy for Int2/High risk MF: where is the field going?,
Alessandro Vannucchi, University of Florence, Italy
17:10pm
Panel Discussion
17:30pm
Wrap up for Day 1
Session V: Other MPNs and Overlap Syndromes
08:30am
Aggressive systemic mastocytosis: emerging therapeutic options,
Deepti Radia, Guy’s and St. Thomas’ NHS Foundation Trust, UK
08:50am
Eosinophilic neoplasms: emerging therapeutic options,
Andreas Reiter, University Medical Centre Mannheim, Germany
09:10am
Myeloproliferative Neoplasm-Unclassifiable (MPN-U),
Donal P McLornan, University College London Hospitals NHS Trust, UK
09:30am
CML the paradigm for MPN,
Elias Jabbour, MD Anderson Cancer Center, USA
09:50am
Panel Discussion
10:10am
Coffee Break
Session VI: Other MPNs and Overlap Syndromes (cont.)
10:30am
Clinical trials in MDS/MPN: How Can we stand alone,
Michael Savona, Vanderbilt University, Nashville, USA
10:50am
Diagnosis and management of MDS/MPN-U,
Andrew Kuykendall, Moffitt Cancer Center, Florida, USA
11:10am
An update on CMML,
Eric Solary, Université Paris-Saclay, France
11:30am
Panel Discussion
11:50pm
Lunch Break
Session VII: Hematopoietic stem cell transplantation (HSCT)
12:50pm
Debate: HSCT for MF: Earlier?,
Ruben Mesa, Wake Forest University in Winston-Salem, USA
13:10pm
Debate: HSCT for MF: Later?,
Ibrahim Yakoub-Agha, Lille University Hospital, Lille, France
13:20pm
Panel discussion
13:40pm
Debate: HSCT for MDS: Earlier?,
Matteo Della Porta, Humanitas University, Italy
14:00pm
Debate: HSCT for MDS: Later?,
Valeria Santini, University of Florence, Italy
14:20pm
Management of iron overload in MDS: who, when?,
Marlijn Hoeks, Radboud University Medical Centre (Radboudumc), Netherlands
14:40pm
Panel discussion
15:00pm
Coffee Break
Session VIII: Myelodysplastic Syndromes (MDS)
15:20pm
Standard and new drugs in higher risk MDS,
Thomas Clazeua, Centre Hospitalier Universitaire de Nice, France
15:40pm
Anemia in MDS and SF3B1 mutated MDS,
Luca Malcovati, IRCCS S. Matteo Hospital Foundation & University of Pavia, Italy
16:00pm
Standard and New drugs in low-risk MDS,
Rami Komrokji, MD Anderson Cancer Center, USA
16:20pm
The resistance to treatment especially hypomethylating agents,
Lucia Messingerova, Slovak Academy of Sciences, Slovakia
16:40pm
Managing secondary AML: from MDS and MPN,
Naval Daver, MD Anderson Cancer Center, USA